Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021.
Lai A, Bergna A, Menzo S, Zehender G, Caucci S, Ghisetti V, Rizzo F, Maggi F, Cerutti F, Giurato G, Weisz A, Turchi C, Bruzzone B, Ceccherini Silberstein F, Clementi N, Callegaro A, Sagradi F, Francisci D, Venanzi Rullo E, Vicenti I, Clementi M, Galli M; collaborative group SCIRE SARS-CoV-2 Italian Research Enterprise. Lai A, et al. Among authors: callegaro a. Virol J. 2021 Aug 14;18(1):168. doi: 10.1186/s12985-021-01638-5. Virol J. 2021. PMID: 34391446 Free PMC article.
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Zazzi M, et al. Among authors: callegaro a. J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. J Antimicrob Chemother. 2009. PMID: 19620134 Free article.
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen.
Prosperi MC, Di Giambenedetto S, Fanti I, Meini G, Bruzzone B, Callegaro A, Penco G, Bagnarelli P, Micheli V, Paolini E, Di Biagio A, Ghisetti V, Di Pietro M, Zazzi M, De Luca A; ARCA cohort. Prosperi MC, et al. Among authors: callegaro a. BMC Med Inform Decis Mak. 2011 Jun 14;11:40. doi: 10.1186/1472-6947-11-40. BMC Med Inform Decis Mak. 2011. PMID: 21672248 Free PMC article.
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010.
Colafigli M, Torti C, Trecarichi EM, Albini L, Rosi A, Micheli V, Manca N, Penco G, Bruzzone B, Punzi G, Corsi P, Parruti G, Bagnarelli P, Monno L, Gonnelli A, Cauda R, Di Giambenedetto S; ARCA, UCSC and Brescia HIV resistance study groups. Colafigli M, et al. Clin Microbiol Infect. 2012 Aug;18(8):E299-304. doi: 10.1111/j.1469-0691.2012.03847.x. Epub 2012 Apr 27. Clin Microbiol Infect. 2012. PMID: 22536753 Free PMC article.
Migration patterns of HIV-1 subtype B virus in Northern Italy.
Lo Presti A, Ciccozzi M, Cella E, Giovanetti M, Zehender G, Valenti D, Iannotti N, Malfatto E, Bernardini C, Maggiolo F, Callegaro A. Lo Presti A, et al. Among authors: callegaro a. New Microbiol. 2013 Jan;36(1):75-9. Epub 2013 Jan 1. New Microbiol. 2013. PMID: 23435818 Free article.
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study.
Gagliardini R, Ciccullo A, Borghetti A, Maggiolo F, Bartolozzi D, Borghi V, Pecorari M, Di Biagio A, Callegaro AP, Bruzzone B, Saladini F, Paolucci S, Maserati R, Zazzi M, Di Giambenedetto S, De Luca A; ARCA Study Group. Gagliardini R, et al. Among authors: callegaro ap. Open Forum Infect Dis. 2018 May 15;5(6):ofy113. doi: 10.1093/ofid/ofy113. eCollection 2018 Jun. Open Forum Infect Dis. 2018. PMID: 29977967 Free PMC article.
Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic.
Lai A, Bergna A, Caucci S, Clementi N, Vicenti I, Dragoni F, Cattelan AM, Menzo S, Pan A, Callegaro A, Tagliabracci A, Caruso A, Caccuri F, Ronchiadin S, Balotta C, Zazzi M, Vaccher E, Clementi M, Galli M, Zehender G. Lai A, et al. Among authors: callegaro a. Viruses. 2020 Jul 24;12(8):798. doi: 10.3390/v12080798. Viruses. 2020. PMID: 32722343 Free PMC article.
Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.
de Salazar A, Dietz J, di Maio VC, Vermehren J, Paolucci S, Müllhaupt B, Coppola N, Cabezas J, Stauber RE, Puoti M, Arenas Ruiz Tapiador JI, Graf C, Aragri M, Jimenez M, Callegaro A, Pascasio Acevedo JM, Macias Rodriguez MA, Rosales Zabal JM, Micheli V, Garcia Del Toro M, Téllez F, García F, Sarrazin C, Ceccherini-Silberstein F; GEHEP-004 cohort, the European HCV Resistance Study Group and the HCV Virology Italian Resistance Network (VIRONET C). de Salazar A, et al. Among authors: callegaro a. J Antimicrob Chemother. 2020 Nov 1;75(11):3349-3358. doi: 10.1093/jac/dkaa304. J Antimicrob Chemother. 2020. PMID: 32772078
At the peak of COVID-19 age and disease severity but not comorbidities are predictors of mortality: COVID-19 burden in Bergamo, Italy.
Novelli L, Raimondi F, Ghirardi A, Pellegrini D, Capodanno D, Sotgiu G, Guagliumi G, Senni M, Russo FM, Lorini FL, Rizzi M, Barbui T, Rambaldi A, Cosentini R, Grazioli LS, Marchesi G, Sferrazza Papa GF, Cesa S, Colledan M, Civiletti R, Conti C, Casati M, Ferri F, Camagni S, Sessa M, Masciulli A, Gavazzi A, Falanga A, DA Pozzo LF, Buoro S, Remuzzi G, Ruggenenti P, Callegaro A, D'Antiga L, Pasulo L, Pezzoli F, Gianatti A, Parigi P, Farina C, Bellasi A, Solidoro P, Sironi S, DI Marco F, Fagiuoli S; HPG23 COVID-19 Study Group. Novelli L, et al. Among authors: callegaro a. Panminerva Med. 2021 Mar;63(1):51-61. doi: 10.23736/S0031-0808.20.04063-X. Epub 2020 Nov 27. Panminerva Med. 2021. PMID: 33244949 Free article.
143 results